Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– ...

AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than 100 ...

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung ...

In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan ...